| 参考文献: |
1. Plumb JA, et al. The activity of verapamil as a resistance modifier in vitro in drug resistant human tumour cell lines is not stereospecific. Biochem Pharmacol. 1990 Feb 15;39(4):787-92. 2. Perrotton T, et al. (R)- and (S)-verapamil differentially modulate the multidrug-resistant protein MRP1. J Biol Chem. 2007 Oct 26;282(43):31542-8. Epub 2007 Jul 22. 3. Faude F, et al. R-(+)-verapamil, S-(-)-verapamil, and racemic verapamil inhibit human retinal pigment epithelial cell contraction. Graefes Arch Clin Exp Ophthalmol. 2000 Jun;238(6):537-41. 4. Karwatsky J, et al. A mechanism for P-glycoprotein-mediated apoptosis as revealed by verapamil hypersensitivity. Biochemistry. 2003 Oct 28;42(42):12163-73. 5. Chen YS, et al. Evaluating the antidiabetic effects of R-verapamil in type 1 and type 2 diabetes mellitus mouse models. PLoS One. 2021 Aug 6;16(8):e0255405. 6. Visani G, et al. Comparative effects of racemic verapamil vs R-verapamil on normal and leukemic progenitors. Ann Hematol. 1993 Jun;66(6):273-6. 7. Wyska E. Pretreatment with R(+)-verapamil significantly reduces mortality and cytokine expression in murine model of septic shock. Int Immunopharmacol. 2009 Apr;9(4):478-90. |